Department of Neurology, University Hospital Cologne, Cologne, Germany.
Institute of Neuroscience and Medicine 3, 4, Research Center Juelich, Juelich, Germany.
Neuro Oncol. 2019 May 6;21(5):585-595. doi: 10.1093/neuonc/noz003.
Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.
脑转移瘤(BM)来自颅外癌症,与显著的发病率和死亡率相关。有效的局部治疗方案包括立体定向放射治疗,包括放射外科或分次外照射放疗,以及手术切除。用于颅内疾病控制的全身治疗的应用也在改善。BM 的诊断、治疗计划和随访最常基于对比增强磁共振成像(MRI)。然而,包括标准 MRI 的解剖成像方式在准确描述治疗后反应性变化和治疗反应方面存在局限性。正电子发射断层扫描(PET)等分子成像技术可对转移瘤的特定代谢和细胞特征进行特征描述,可能提供补充解剖 MRI 的临床相关信息。在这里,神经肿瘤学反应评估工作组根据经组织学和/或临床结果验证的研究证据,就 PET 成像在 BM 患者的临床管理中的应用提供建议。